Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Extreme Language Ultra-High Potency
The newest generation of small-molecule therapies bring containment needs well beyond those of conventional HPAPIs. What does this mean for the pharma lexicon – and the pharma landscape? read more
How Sports Stars and Drugs Keep Getting Reinvented
Reinvention is everywhere. Products get updated, industries change course, and ideas we once treated as finished suddenly come back in a new form. Something that felt permanent five years ago can look completely different today, redesigned for a new audience or a new moment. read more
Post-Approval Change Management
Achieving global approval for a single change may take three to five years, but inefficient lifecycle change management rarely registers as a crisis. read more
Leveraging AI and ML to Optimize Drug Discovery – a CRO Perspective
CROs supporting early-stage drug discovery projects are establishing their own internal AI platforms to address their clients’ needs in an evolving field. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Kindeva Appoints Chief Transformation Officer
Monday, July 13, 2026
Kindeva announced the appointment of Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and ... read more
Axplora Manufacturing Sites Earn EcoVadis Ratings Across European Network
Thursday, July 09, 2026
Axplora reported updated EcoVadis sustainability ratings for four of its European manufacturing sites, with one site achieving platinum status and ... read more
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Thursday, July 09, 2026
Porton Advanced announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for ... read more
WuXi Biologics’ MFG8 Facility Gains FDA Pre License Inspection Approval For Autoimmune Therapy
Thursday, July 09, 2026
WuXi Biologics has received FDA pre license inspection (PLI) approval for its MFG8 drug substance manufacturing facility in Hebei, clearing the way ... read more
Evonik Invests $100M to Upgrade Drug Substance Manufacturing Site in Lafayette, IN
Wednesday, July 08, 2026
Evonik announced it is making a significant investment to strengthen manufacturing capabilities at its Tippecanoe Labs site in Lafayette, Indiana. read more